GH Research PLC (GHRS)
| Market Cap | 1.47B +101.0% |
| Revenue (ttm) | n/a |
| Net Income | -56.41M |
| EPS | -0.91 |
| Shares Out | 68.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 352,033 |
| Open | 23.01 |
| Previous Close | 23.25 |
| Day's Range | 21.21 - 23.61 |
| 52-Week Range | 11.32 - 25.94 |
| Beta | 1.31 |
| Analysts | Strong Buy |
| Price Target | 39.50 (+84.32%) |
| Earnings Date | May 14, 2026 |
About GHRS
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for GHRS stock is "Strong Buy." The 12-month stock price target is $39.5, which is an increase of 84.32% from the latest price.
News
GH Research announces publication of Phase 2a results for mebufotenin
GH Research (GHRS) announced the publication of the full results from its Phase 2a trial in postpartum depression and the acceptance of two oral presentations at the 37th World Congress…
GH Research Announces Publication of Phase 2a Postpartum Depression Results
DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance o...
GH Research price target lowered to $65 from $70 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on GH Research (GHRS) to $65 from $70 and keeps a Buy rating on the shares. The firm cites share count dilution from…
GH Research price target raised to $35 from $25 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on GH Research (GHRS) to $35 from $25 and keeps an Overweight rating on the shares. GH Research is viewed as operating in…
GH Research price target lowered to $39 from $42 at Citizens
Citizens analyst Jason Butler lowered the firm’s price target on GH Research (GHRS) to $39 from $42 and keeps an Outperform rating on the shares. GH Research reported continued progress…
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a treatment update and an analyst initiation. EARNINGS: On Thursday, GH…
GH Research Earnings release: Q1 2026
GH Research released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
GH Research files $400M mixed securities shelf
09:22 EDT GH Research (GHRS) files $400M mixed securities shelf
GH Research reports Q1 EPS (31c), consensus (26c)
“The first quarter of 2026 marks progress as planned toward our global GH001 Phase 3 pivotal program,” said Velichka Valcheva, CEO.
GH Research Registration statement: Registration filing
GH Research filed a registration statement on May 14, 2026, providing details about a securities offering with the SEC.
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enr...
GH Research Slides: Corporate presentation
GH Research has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
GH Research Announces Pricing of $117.5 Million Underwritten Offering
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing ...
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research
The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has b...
GH Research ‘welcomes’ Executive Order to accelerate mental illness treatments
GH Research (GHRS) issued a statement “welcoming” the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedel...
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing ...
Psychedelic stocks rally with Trump's support
An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
GH Research announces publication of Phase 2b results for mebufotenin
GH Research (GHRS) announced two peer-reviewed publications from its Phase 2b clinical program of GH001 in treatment-resistant depression: the primary trial results in JAMA Psychiatry, and a new analy...
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing ...
GH Research price target raised to $34 from $29 at Guggenheim
Guggenheim analyst Eddie Hickman raised the firm’s price target on GH Research (GHRS) to $34 from $29 and keeps a Buy rating on the shares after the company reported FY25…
GH Research price target raised to $42 from $39 at Citizens
Citizens raised the firm’s price target on GH Research (GHRS) to $42 from $39 and keeps an Outperform rating on the shares. GH Research reported Q4 results highlighting continued progress…
GH Research reports FY25 EPS (79c), consensus (82c)
In 2025, the Company completed its Phase 2b trial of GH001 in treatment-resistant depression and presented the full dataset at the 2025 American Society of Clinical Psychopharmacology Annual Meeting i...